

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6984991

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ISH KHANNA	09/17/2020
SIVARAM PILLARISETTI	09/17/2020
RECEIVING PARTY DATA	
Name:	NEPHRODI THERAPEUTICS, INC.
Street Address:	1606 CHESTNUT STREET
Internal Address:	UNIT 3
City:	PHILADELPHIA
State/Country:	PENNSYLVANIA
Postal Code:	19103
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17506236
CORRESPONDENCE DATA	
Fax Number:	(412)454-5060
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(412)454-5000
Email:	docketingpgh@troutman.com
Correspondent Name:	TROUTMAN PEPPER HAMILTON SANDERS LLP
Address Line 1:	UNION TRUST BUILDING
Address Line 2:	501 GRANT STREET, SUITE 300
Address Line 4:	PITTSBURGH, PENNSYLVANIA 15219
ATTORNEY DOCKET NUMBER:	146075.000311
NAME OF SUBMITTER:	MICHAEL VERTULLO
SIGNATURE:	/Michael Vertullo/
DATE SIGNED:	10/22/2021
Total Attachments: 12	
source=146075_000311_KHANNA_PILLARISETTI_to_NEPHRODI_THERAPEUTICS_INC#page1.tif	
source=146075_000311_KHANNA_PILLARISETTI_to_NEPHRODI_THERAPEUTICS_INC#page2.tif	
source=146075_000311_KHANNA_PILLARISETTI_to_NEPHRODI_THERAPEUTICS_INC#page3.tif	

source=146075_000311_KHANNA_PILLARISSETTI_to_NEPHRODI_THERAPEUTICS_INC#page4.tif
source=146075_000311_KHANNA_PILLARISSETTI_to_NEPHRODI_THERAPEUTICS_INC#page5.tif
source=146075_000311_KHANNA_PILLARISSETTI_to_NEPHRODI_THERAPEUTICS_INC#page6.tif
source=146075_000311_KHANNA_PILLARISSETTI_to_NEPHRODI_THERAPEUTICS_INC#page7.tif
source=146075_000311_KHANNA_PILLARISSETTI_to_NEPHRODI_THERAPEUTICS_INC#page8.tif
source=146075_000311_KHANNA_PILLARISSETTI_to_NEPHRODI_THERAPEUTICS_INC#page9.tif
source=146075_000311_KHANNA_PILLARISSETTI_to_NEPHRODI_THERAPEUTICS_INC#page10.tif
source=146075_000311_KHANNA_PILLARISSETTI_to_NEPHRODI_THERAPEUTICS_INC#page11.tif
source=146075_000311_KHANNA_PILLARISSETTI_to_NEPHRODI_THERAPEUTICS_INC#page12.tif

CONFIRMATORY PATENT ASSIGNMENT AGREEMENT

This Confirmatory Patent Assignment Agreement ("Agreement") is made September 17, 2020 by and between Ish Khanna ("Khanna"), NeuroPN Therapeutics with an address of 4989 Peachtree Parkway, Suite 200, Peachtree Parkway, GA 30092 ("NeuroPN"), and NephroDI Therapeutics, Inc., having an address of 2324 Wallace Street, Philadelphia, PA 19130 ("NephroDI") (each individually, a "Party" and collectively, the "Parties").

WHEREAS, Khanna is an inventor of certain new and useful invention(s) as set forth and disclosed in the patent application(s) listed in Schedule A attached hereto (the "Invention");

WHEREAS, Khanna is a founder of NeuroPN;

WHEREAS, Khanna is also a founder of NephroDI and Khanna and NephroDI are parties to the Founder Nondisclosure, Invention Assignment, Nonsolicitation and Noncompete Agreement dated August 23, 2017, whereby Khanna assigns and is obligated to assign certain inventions (as defined therein) to NephroDI;

WHEREAS, NephroDI is desirous of acquiring each of Khanna's and NeuroPN's entire right, title and interest in and to said Invention and in and to any and all Letters Patent of the United States and foreign countries that may be obtained therefor; and

WHEREAS, the Parties wish to confirm and restate the flow of right, title, and interest in the Invention between the Parties;

NOW, THEREFORE, in consideration of mutual covenants and agreements set forth below, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

1. NeuroPN does hereby waive and otherwise disclaim any and all right, title and interest in and to the Invention, as well as any patent applications filed on the Invention as may be set forth in Exhibit A, including any applications which claim priority to the scheduled application(s), any application(s) to which the scheduled application(s) claim priority, and any continuations, continuations-in-part, divisions, registrations, reissues, re-examinations or extensions thereof, whether in the U.S. or any foreign country, and in and to any and all patents of the United States and foreign countries which may be issued for said Invention, including all rights to claim priority rights deriving from the Invention; all causes of action and remedies related to the Invention (including, without limitation, the right to sue for past, present, or future infringement, misappropriation or violation of rights related to any of the foregoing and the right to collect royalties and other payments under or on account of any of the foregoing) in favor of Khanna.

2. Khanna does hereby sell, assign, transfer and set over unto NephroDI, its legal representatives, successors, and assigns, his entire right, title and interest in and to the Invention, as well as any patent applications filed on the Invention as may be set forth in Exhibit A, including any applications which claim priority to the scheduled application(s), any

continuations-in-part, divisions, registrations, reissues, re-examinations or extensions thereof, whether in the U.S. or any foreign country, and in and to any and all patents of the United States and foreign countries which may be issued for said Invention, including all rights to claim priority rights deriving from the Invention; all causes of action and remedies related to the Invention (including, without limitation, the right to sue for past, present, or future infringement, misappropriation or violation of rights related to any of the foregoing and the right to collect royalties and other payments under or on account of any of the foregoing) in favor of NephroDI.

3. No party shall not execute any writing or do any act whatsoever conflicting with the terms and conditions of this Assignment. Each party will, at any time upon request, without further or additional consideration, but at the expense of NephroDI, execute such additional assignments and other writings and do such additional acts as Assignee may deem necessary or desirable to perfect NephroDI's enjoyment of this grant, and render all necessary assistance in making the application for or obtaining original patents or applications, continuations, continuations-in-part, divisions, registrations, reissues, re-examinations or extensions thereof, whether in the U.S. or any foreign country, for said Invention, and in enforcing any rights or choses in action accruing as a result of such applications or patents, by giving testimony in any and all proceedings or transactions involving such applications or patents, and by executing preliminary statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind and inure to the benefit of the assigns and legal representatives of the parties.

4. The undersigned hereby grant(s) the firm of Troutman Pepper Hamilton Sanders LLP the power to insert on this Assignment any further identification, including the country, application number, filing date and/or title, which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office or other patent office for recordation of this document.

5. The undersigned requests that any patents that may be issued for said Invention be issued to NephroDI, its legal representatives, successors or assigns, as an owner of Khanna's and NeuroPN's entire right, title and interest in and to said patent and the Invention covered thereby.

Agreed and accepted:

Date: Sept 17, 2020Ish Khanna
Ish KHANNA**ACKNOWLEDGMENT**STATE OF Georgia)
)
COUNTY OF Gwinnett) SS:

On this 17th day of September, 2020, before me, a Notary Public, the undersigned officer, personally appeared **Ish Khanna**, to me known (or satisfactorily proven) to be the person named in and who executed the above instrument, and acknowledged to me that he executed the same for the uses and purposes therein set forth.

S E A L



[Signature]
Notary PublicMy commission expires 4-27-2023

Agreed and accepted:

Date: 9-17-2020Signature: S. Pillarisehi
By: S. Pillarisehi
Title: Founder
NeuroPN,**ACKNOWLEDGMENT**STATE OF Georgia)
COUNTY OF Gwinnett) SS:

On this 17th day of September, 2020, before me, a Notary Public, the undersigned officer, personally appeared S. Pillarisehi, to me known (or satisfactorily proven) to be the person named in and who executed the above instrument, and acknowledged to me that he executed the same for the uses and purposes therein set forth.

SEAL


Notary PublicMy commission expires 4-27-2023

Agreed and accepted:

Date: 9/17/2020

Signature: [Signature]
 By: Rachael Hagan
 Title: CEO
 NephroDI Therapeutics, Inc.

ACKNOWLEDGMENT


STATE OF Pennsylvania)
)
 COUNTY OF Philadelphia) SS:

On this 17th day of September, 2020, before me, a Notary Public, the undersigned officer, personally appeared Rachael A. Hagan to me known (or satisfactorily proven) to be the person named in and who executed the above instrument, and acknowledged to me that he executed the same for the uses and purposes therein set forth.

SEAL

[Signature]
 Notary Public

My commission expires _____



SCHEDULE A

Country	Patent Application No.	Filing Date	Title
US	62/452,616	01/31/2017	Managing Nephrogenic Diabetes Insipidus
PCT	PCT/US2018/016184	01/31/2018	Managing Nephrogenic Diabetes Insipidus
US	16/491,990	01/31/2018	Managing Nephrogenic Diabetes Insipidus
EP	18748236.9	01/31/2018	Managing Nephrogenic Diabetes Insipidus
CA	3071385	01/31/2018	Managing Nephrogenic Diabetes Insipidus
AU	2018217038	01/31/2018	Managing Nephrogenic Diabetes Insipidus
JP	{to be assigned}	01/31/2018	Managing Nephrogenic Diabetes Insipidus

CONFIRMATORY PATENT ASSIGNMENT AGREEMENT

This Confirmatory Patent Assignment Agreement ("Agreement") is made September 17, 2020 by and between Sivaram Pillarisetti ("Pillarisetti"), NeuroPN Therapeutics with an address of 4989 Peachtree Parkway, Suite 200, Peachtree Parkway, GA 30092 ("NeuroPN"), and NephroDI Therapeutics, Inc., having an address of 2324 Wallace Street, Philadelphia, PA 19130 ("NephroDI") (each individually, a "Party" and collectively, the "Parties").

WHEREAS, Pillarisetti is an inventor of certain new and useful invention(s) as set forth and disclosed in the patent application(s) listed in **Schedule A** attached hereto (the "Invention");

WHEREAS, Pillarisetti is a founder of NeuroPN;

WHEREAS, Pillarisetti is also a founder of NephroDI and Pillarisetti and NephroDI are parties to the Founder Nondisclosure, Invention Assignment, Nonsolicitation and Noncompete Agreement dated August 23, 2017, whereby Pillarisetti assigns and is obligated to assign certain inventions (as defined therein) to NephroDI;

WHEREAS, NephroDI is desirous of acquiring each of Pillarisetti's and NeuroPN's entire right, title and interest in and to said Invention and in and to any and all Letters Patent of the United States and foreign countries that may be obtained therefor; and

WHEREAS, the Parties wish to confirm and restate the flow of right, title, and interest in the Invention between the Parties;

NOW, THEREFORE, in consideration of mutual covenants and agreements set forth below, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

1. NeuroPN does hereby waive and otherwise disclaim any and all right, title and interest in and to the Invention, as well as any patent applications filed on the Invention as may be set forth in Exhibit A, including any applications which claim priority to the scheduled application(s), any application(s) to which the scheduled application(s) claim priority, and any continuations, continuations-in-part, divisions, registrations, reissues, re-examinations or extensions thereof, whether in the U.S. or any foreign country, and in and to any and all patents of the United States and foreign countries which may be issued for said Invention, including all rights to claim priority rights deriving from the Invention; all causes of action and remedies related to the Invention (including, without limitation, the right to sue for past, present, or future infringement, misappropriation or violation of rights related to any of the foregoing and the right to collect royalties and other payments under or on account of any of the foregoing) in favor of Pillarisetti.

2. Pillarisetti does hereby sell, assign, transfer and set over unto NephroDI, its legal representatives, successors, and assigns, his entire right, title and interest in and to the Invention, as well as any patent applications filed on the Invention as may be set forth in Exhibit A, including any applications which claim priority to the scheduled application(s), any

continuations-in-part, divisions, registrations, reissues, re-examinations or extensions thereof, whether in the U.S. or any foreign country, and in and to any and all patents of the United States and foreign countries which may be issued for said Invention, including all rights to claim priority rights deriving from the Invention; all causes of action and remedies related to the Invention (including, without limitation, the right to sue for past, present, or future infringement, misappropriation or violation of rights related to any of the foregoing and the right to collect royalties and other payments under or on account of any of the foregoing) in favor of NephroDI.

3. No party shall not execute any writing or do any act whatsoever conflicting with the terms and conditions of this Assignment. Each party will, at any time upon request, without further or additional consideration, but at the expense of NephroDI, execute such additional assignments and other writings and do such additional acts as Assignee may deem necessary or desirable to perfect NephroDI's enjoyment of this grant, and render all necessary assistance in making the application for or obtaining original patents or applications, continuations, continuations-in-part, divisions, registrations, reissues, re-examinations or extensions thereof, whether in the U.S. or any foreign country, for said Invention, and in enforcing any rights or choses in action accruing as a result of such applications or patents, by giving testimony in any and all proceedings or transactions involving such applications or patents, and by executing preliminary statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind and inure to the benefit of the assigns and legal representatives of the parties.

4. The undersigned hereby grant(s) the firm of Troutman Pepper Hamilton Sanders LLP the power to insert on this Assignment any further identification, including the country, application number, filing date and/or title, which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office or other patent office for recordation of this document.

5. The undersigned requests that any patents that may be issued for said Invention be issued to NephroDI, its legal representatives, successors or assigns, as an owner of Khanna's and NeuroPN's entire right, title and interest in and to said patent and the Invention covered thereby.

Agreed and accepted:

Date: 9-17-2020


S. Pillarisetti
Sivaram Pillarisetti

ACKNOWLEDGMENT

STATE OF Georgia
COUNTY OF Gwinnett

)
) SS:
)

On this 17th day of September, 2020, before me, a Notary Public, the undersigned officer, personally appeared **Sivaram Pillarisetti**, to me known (or satisfactorily proven) to be the person named in and who executed the above instrument, and acknowledged to me that he executed the same for the **uses and purposes** therein set forth.



Karen Solorzano
Notary Public

My commission expires 4-27-2023

Agreed and accepted:

Date: 9/24/20

Signature: ISH KHANNA
By: ISH KHANNA
Title: CEO
NeuroPN,


ACKNOWLEDGMENT

STATE OF Georgia
COUNTY OF Gwinnett

)
)
) SS:


On this 17th day of September, 2020, before me, a Notary Public, the undersigned officer, personally appeared ISH KHANNA, to me known (or satisfactorily proven) to be the person named in and who executed the above instrument, and acknowledged to me that he executed the same for the uses and purposes therein set forth.

SEAL



Karen Solorzano
Notary Public

My commission expires 4-27-2023



Agreed and accepted:


Date: 9/17/2020Signature: [Signature]
By: Richard A. Hagan
Title: CEO
NephroDI Therapeutics, Inc.**ACKNOWLEDGMENT**STATE OF Pennsylvania)
)
COUNTY OF Philadelphia) SS:

On this 17th day of September, 2020, before me, a Notary Public, the undersigned officer, personally appeared Richard A. Hagan to me known (or satisfactorily proven) to be the person named in and who executed the above instrument, and acknowledged to me that he executed the same for the uses and purposes therein set forth.

S E A L

[Signature]
Notary Public

My commission expires _____



SCHEDULE A

Country	Patent Application No.	Filing Date	Title
US	62/452,616	01/31/2017	Managing Nephrogenic Diabetes Insipidus
PCT	PCT/US2018/016184	01/31/2018	Managing Nephrogenic Diabetes Insipidus
US	16/491,990	01/31/2018	Managing Nephrogenic Diabetes Insipidus
EP	18748236.9	01/31/2018	Managing Nephrogenic Diabetes Insipidus
CA	3071385	01/31/2018	Managing Nephrogenic Diabetes Insipidus
AU	2018217038	01/31/2018	Managing Nephrogenic Diabetes Insipidus
JP	{to be assigned}	01/31/2018	Managing Nephrogenic Diabetes Insipidus